ArticleDiscover oncology2025
S-adenosylmethionine enhances anti-PD-1 efficacy in uveal melanoma by targeting EZH2.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amino acid metabolic reprogramming by gut microbiota: a novel metabolic checkpoint in the tumor microenvironment.Gut microbes · 2026Review
- One-carbon metabolism in cancer immunity: T-cell fitness, epigenetic programming, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of S-adenosylmethionine (SAM) on enhancing anti-programmed death 1 (PD-1) therapy in uveal melanoma (UM) by targeting Enhancer of Zeste homolog 2 (EZH2). The synergistic effect of SAM in combination with the PD-1 inhibitor Pembrolizumab was verified by screening its target of action, assessing its effect on cell viability, proliferation, migration, and apoptosis.
methodsWe used network pharmacology combined with transcriptomics data, then combined GEOquery tool and PharmMapper database to select the targets of SAM in treating UM, and performed differential gene expression analysis using the limma algorithm package. Multidimensional clustering heatmap and functional enrichment analysis were performed using the ComplexHeatmap and clusterProfiler tools to analyze the mechanism of SAM in targeting key targets in UM. In addition, we developed a SAM targeted accurate prognostic prediction system for UM by integrating multi-omics data and applying machine learning algorithms. Finally, to validate the effects of SAM targeting key targets of UM, we examined the effects of SAM and its combination with Pembrolizumab on UM cell viability, proliferation, migration, and apoptosis using CCK-8, transwell migration assay, and flow cytometry.
resultsThe expression of EZH2 was significantly higher in various cancer types than in normal tissues (P < 0.05), and its high expression was closely related to the infiltration pattern of specific types of immune cells. Further Kaplan-Meier survival analysis showed that high EZH2 expression was associated with worse patient outcomes, particularly for CD8 + T cells, NK cell-related immune outcomes. However, SAM significantly inhibited the proliferation of MUM-2B and C-918 cell lines with IC50 values of 224.4 µmol/L and 220.9 µmol/L, respectively, and down-regulated the mRNA expression levels of key genes EZH2 and CD279. Finally, SAM showed synergistic effects when combined with Pembrolizumab, significantly enhanced the inhibitory effect on EZH2, and effectively inhibited cell proliferation, migration, and promoted apoptosis.
conclusionAs a potential anticancer drug, SAM can not only significantly inhibit the proliferation and migration of UM cells, but also promote apoptosis. In particular, SAM showed a stronger antitumor effect when it was combined with Pembrolizumab, providing a theoretical basis for the development of new strategies based on EZH2-targeted therapy and suggesting the potential of this combination therapy in clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.